Histology
Non-Small Cell Carcinoma
CI-CAN-00001292Explore in graph →
1,752 active trials47 approved drugs589 evidence items
- NCIt
- C65151
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00001292Explore in graph →
Clinical trials
6,757 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,046)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05111197 | Local Ablative Stereotactic Radiotherapy for Residual Hypermetabolic Lesion in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Long-term Responders to Immunotherapy(TRAILOCLORI01) | unknown | Phase 3 | 112 | Institut Cancerologie de l'OuestOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT05718167 | TQB2450 Injection Combined With Chemotherapy Followed by Sequential Combination With Anlotinib Hydrochloride Capsule for First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer. | unknown | Phase 3 | 570 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
| 1 |
| Feb 14, 2023 |
| clinicaltrials |
| NCT03856411 | A Study to Evaluate the Efficacy and Safety of Toripalimab or Placebo Combined With Chemotherapy in Treatment-naive Advanced NSCLC | completed | Phase 3 | 465 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Feb 1, 2023 | clinicaltrials |
| NCT03196986 | mil60 Versus Bevacizumab in Patients With Treatment-naïve Non-squamous Non-small Cell Lung Cancer | completed | Phase 3 | 517 | Beijing Mabworks Biotech Co., Ltd.INDUSTRY | 1 | Jan 31, 2023 | clinicaltrials |
| NCT03849768 | A Study to Evaluate Safety and Efficacy of HS-10296 as First-Line Treatment in Patients | unknown | Phase 3 | 429 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 20, 2023 | clinicaltrials |
| NCT03682224 | Exparel and Marcaine for Pain Management in Thoracoscopic Lobectomy Patients(BEMP) | completed | Phase 3 | 57 | Southern Illinois UniversityOTHER | 1 | Jan 12, 2023 | clinicaltrials |
| NCT02813785 | A Study of Atezolizumab Compared With Docetaxel in Non-Small Cell Lung Cancer (NSCLC) After Failure With Platinum-Containing Chemotherapy(IMpower210) | completed | Phase 3 | 565 | Hoffmann-La RocheINDUSTRY | 5 | Jan 10, 2023 | clinicaltrials |
| NCT05661240 | Phase Ⅱ/Ⅲ Clinical Study of Tumor Treating Fields （EFE-P100）Combined With Docetaxel in the Treatment of Stage IV Non-small Cell Lung Cancer Patients With Disease Progression After Platinum-based Chemotherapy and Anti-programmed Death 1（PD-1)/Programmed Cell Death-Ligand 1(PD-L1) Antibody Treatment | unknown | Phase 2 / Phase 3 | 348 | Jiangsu Healthy Life Innovation Medical Technology Co., LtdINDUSTRY | 1 | Dec 22, 2022 | clinicaltrials |
| NCT05648071 | First-Line Treatment for Advanced Non-squamous Non-Small-Cell Lung Cancer With Negative Driver Gene: a Single-center, Single-Arm Trial(SPBPDC) | unknown | Phase 3 | 60 | Qianfoshan HospitalOTHER | 1 | Dec 13, 2022 | clinicaltrials |
| NCT00858364 | Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy | terminated | Phase 3 | 2,549 | AmgenINDUSTRY | 37 | Nov 30, 2022 | clinicaltrials |
| NCT05042375 | A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer | unknown | Phase 3 | 450 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Nov 17, 2022 | clinicaltrials |
| NCT03515629 | REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer | terminated | Phase 3 | 5 | Regeneron PharmaceuticalsINDUSTRY | 3 | Nov 16, 2022 | clinicaltrials |
| NCT05605613 | PD-1 Antibody in Addition to BACE in Patients With NSCLC: A Randomised Controlled Trial | unknown | Phase 2 / Phase 3 | 150 | Xuhua DuanOTHER | 1 | Nov 9, 2022 | clinicaltrials |
| NCT02066636 | A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy Regimen(CheckMate153) | completed | Phase 3 | 1,428 | Bristol-Myers SquibbINDUSTRY | 2 | Oct 27, 2022 | clinicaltrials |
| NCT01968941 | Stereotactic Body Radiotherapy Versus Conventional Radiotherapy in Medically-Inoperable Non-Small Lung Cancer Patients(LUSTRE) | completed | Phase 3 | 324 | Ontario Clinical Oncology Group (OCOG)OTHER | 1 | Sep 21, 2022 | clinicaltrials |
| NCT04942275 | Lung Perfusion PET / CT Using Ga68-MAA for Preservation of Lung Function During Stereotactic Pulmonary Radiation Therapy(PEGASUS) | unknown | Phase 2 / Phase 3 | 60 | University Hospital, BrestOTHER | 1 | Sep 19, 2022 | clinicaltrials |
| NCT03922997 | A Study to Investigate the Safety and Efficacy of Atezolizumab in Previously-Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | completed | Phase 3 | 101 | Hoffmann-La RocheINDUSTRY | 1 | Sep 9, 2022 | clinicaltrials |
| NCT04342377 | The Canada Lymph Node Score Project: A Crossover Trial(CLNS) | completed | Phase 3 | 80 | St. Joseph's Healthcare HamiltonOTHER | 1 | Jul 27, 2022 | clinicaltrials |
| NCT00347412 | Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer | completed | Phase 3 | 903 | Cellectar Biosciences, Inc.INDUSTRY | 12 | Jul 25, 2022 | clinicaltrials |
| NCT00966914 | Phase 3 Study of Tavocept Versus Placebo in Patients With Newly Diagnosed or Relapsed Advanced Primary Adenocarcinoma of the Lung Treated With Docetaxel or Paclitaxel Plus Cisplatin | completed | Phase 3 | 540 | BioNumerik Pharmaceuticals, Inc.INDUSTRY | 6 | Jul 13, 2022 | clinicaltrials |
| NCT04951635 | A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer | recruiting | Phase 3 | 150 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 16, 2022 | clinicaltrials |
| NCT00913705 | Neoadjuvant or Adjuvant Chemotherapy in Patients With Operable Non-small-cell Lung Cancer(NATCH) | completed | Phase 3 | 624 | Spanish Lung Cancer GroupOTHER | 0 | Jun 13, 2022 | clinicaltrials |
| NCT02142738 | Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024) | completed | Phase 3 | 305 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 13, 2022 | clinicaltrials |
| NCT01487174 | KD019 Versus Erlotinib in Subjects With Stage IIIB/IV Non Small Cell Lung Cancer With Progression After First- or Second-Line Chemotherapy | terminated | Phase 3 | 8 | Kadmon Corporation, LLCINDUSTRY | 1 | May 13, 2022 | clinicaltrials |
| NCT05346952 | A Study of TQB2450 Injection Plus Chemotherapy Followed by TQB2450 Plus Anlotinib Versus Tislelizumab Plus Chemotherapy Followed by Tislelizumab in the Treatment of First-line Non-squamous Non-small Cell Lung Cancer(NSCLC). | unknown | Phase 3 | 390 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Apr 26, 2022 | clinicaltrials |
| NCT04325763 | A Study of TQB2450 in Subjects With Stage III Non-Small Cell Lung Cancer(NSCLC) | unknown | Phase 3 | 315 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Mar 31, 2022 | clinicaltrials |
| NCT04633564 | MYL-1402O Compared With Avastin®, in Patients With Stage IV nsNSCLC | completed | Phase 3 | 671 | Mylan Pharmaceuticals IncINDUSTRY | 17 | Mar 16, 2022 | clinicaltrials |
| NCT02810457 | Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung Cancer(AVANA) | completed | Phase 3 | 731 | Centus Biotherapeutics LimitedINDUSTRY | 24 | Mar 10, 2022 | clinicaltrials |
| NCT01951469 | Gefitinib With or Without Chemotherapy in Brain Metastases From Non-small Cell Lung Cancer | unknown | Phase 3 | 160 | Sun Yat-sen UniversityOTHER | 1 | Mar 8, 2022 | clinicaltrials |
| NCT02607592 | A Prospective Multi-center Phase III Randomized Controlled Trial(NACA) | unknown | Phase 3 | 293 | Sun Yat-sen UniversityOTHER | 1 | Feb 25, 2022 | clinicaltrials |
| NCT04762459 | Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour Resection(APEX) | enrolling by invitation | Phase 3 | 606 | Chinese Academy of Medical SciencesOTHER | 1 | Feb 24, 2022 | clinicaltrials |
| NCT05209256 | Alflutinib Versus Alflutinib Plus Chemotherapy for NSCLC | unknown | Phase 2 / Phase 3 | 90 | The First Affiliated Hospital of Henan University of Science and TechnologyOTHER | 0 | Jan 26, 2022 | clinicaltrials |
| NCT05204628 | A Study to Evaluate and Compare the Efficacy and Safety of XZP-3621 Versus Crizotinib | unknown | Phase 3 | 238 | Xuanzhu Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 24, 2022 | clinicaltrials |
| NCT00982111 | First-line Treatment of Patients With Stage IV Nonsquamous Non-Small Cell Lung Cancer With Necitumumab (IMC-11F8) and Pemetrexed-Cisplatin(INSPIRE) | completed | Phase 3 | 633 | Eli Lilly and CompanyINDUSTRY | 20 | Jan 11, 2022 | clinicaltrials |
| NCT05169801 | To Compare the Efficacy and Safety of BP102 vs. Avastin® in Combination With Paclitaxel/Carboplatin in First-line Treatment of Advanced or Relapsed NSCLC | completed | Phase 3 | 520 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Dec 27, 2021 | clinicaltrials |
| NCT02743923 | Cisplatin-Pemetrexed Compared With Carboplatin-Paclitaxel-Bevacizumab in KRAS Mutated Non-small Cell Lung Cancer | unknown | Phase 3 | 203 | The Netherlands Cancer InstituteOTHER | 1 | Dec 21, 2021 | clinicaltrials |
| NCT04316364 | A Trial of SHR-1316/Placebo in Combination With Chemotherapy in Patients With Resectable NSCLC | recruiting | Phase 3 | 537 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Nov 4, 2021 | clinicaltrials |
| NCT00948675 | Study of Participants With Advanced Non-Small Cell Lung Cancer | completed | Phase 3 | 361 | Eli Lilly and CompanyINDUSTRY | 1 | Oct 29, 2021 | clinicaltrials |
| NCT00365963 | Web-based Intervention for Lung Cancer Patients and Their Informal Caregivers | completed | Phase 3 | 284 | University of Wisconsin, MadisonOTHER | 1 | Oct 6, 2021 | clinicaltrials |
| NCT01905657 | Study of Two Doses of Pembrolizumab (MK-3475) Versus Docetaxel in Previously Treated Participants With Non-Small Cell Lung Cancer (MK-3475-010/KEYNOTE-010) | completed | Phase 2 / Phase 3 | 1,034 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Oct 6, 2021 | clinicaltrials |
| NCT02366143 | A Study of Atezolizumab in Combination With Carboplatin Plus (+) Paclitaxel With or Without Bevacizumab Compared With Carboplatin+Paclitaxel+Bevacizumab in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)(IMpower150) | completed | Phase 3 | 1,202 | Hoffmann-La RocheINDUSTRY | 26 | Sep 23, 2021 | clinicaltrials |
| NCT03329911 | A Comparative Study of BAT1706 and EU Avastin® in Patients With Advanced Non Squamous Non Small Cell Lung Cancer | completed | Phase 3 | 651 | Bio-Thera SolutionsINDUSTRY | 5 | Sep 14, 2021 | clinicaltrials |
| NCT02737501 | ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants(ALTA-1L) | completed | Phase 3 | 275 | Ariad PharmaceuticalsINDUSTRY | 19 | Aug 20, 2021 | clinicaltrials |
| NCT04964479 | A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus K Drug in the Treatment of First-line Non-small Cell Lung Cancer(NSCLC) | unknown | Phase 3 | 375 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Aug 20, 2021 | clinicaltrials |
| NCT02367781 | A Study of Atezolizumab in Combination With Carboplatin Plus (+) Nab-Paclitaxel Compared With Carboplatin+Nab-Paclitaxel in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)(IMpower130) | completed | Phase 3 | 723 | Hoffmann-La RocheINDUSTRY | 8 | Aug 9, 2021 | clinicaltrials |
| NCT00668707 | Adjuvant Melatonin for Prevention of Lung Cancer Recurrence and Mortality(AMPLCaRe) | completed | Phase 3 | 709 | The Canadian College of Naturopathic MedicineOTHER | 1 | Aug 3, 2021 | clinicaltrials |
| NCT02448797 | Icotinib as Adjuvant Therapy Compared With Standard Chemotherapy in Stage II-IIIA NSCLC With EGFR-mutation(EVIDENCE) | unknown | Phase 3 | 320 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jul 20, 2021 | clinicaltrials |
| NCT04968002 | Application of Pablizumab Combined With Apatinib and Chemotherapy in Resectable Non-small Cell Lung Cancer： A Prospective, Single Arm, Single Center Phase II Clinical Study of Neoadjuvant Therapy | unknown | Phase 2 / Phase 3 | 40 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jul 20, 2021 | clinicaltrials |
| NCT04951648 | A Phase III Study to Assess the Efficacy and Safety of Almonertinib Versus Platinum-based Chemotherapy as First-line Therapy in Patients With Locally Advanced or Metastatic NSCLC Harbouring Uncommon EGFR Mutation | unknown | Phase 3 | 220 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 7, 2021 | clinicaltrials |
| NCT02768558 | Cisplatin and Etoposide Plus Radiation Followed By Nivolumab/Placebo For Locally Advanced NSCLC | terminated | Phase 3 | 20 | RTOG Foundation, Inc.OTHER | 1 | Jun 2, 2021 | clinicaltrials |
Data updated 24 days agoSource updated Feb 21, 2023source: clinicaltrials